ContributorsPublishersAdvertisers

Sugemalimab Plus Chemo Significantly Improves Survival in Frontline Stage IV NSCLC

onclive.com
 2022-01-19

The addition of the PD-L1 inhibitor sugemalimab to chemotherapy significantly improved overall survival compared with chemotherapy alone in the frontline treatment of patients with stage IV non–small cell lung cancer. The addition of the PD-L1 inhibitor sugemalimab to chemotherapy significantly improved overall survival (OS) compared with chemotherapy alone...

www.onclive.com

Comments / 0

Comments / 0